Literature DB >> 2345961

Pradimicin A inhibition of human immunodeficiency virus: attenuation by mannan.

A Tanabe-Tochikura1, T S Tochikura, O Yoshida, T Oki, N Yamamoto.   

Abstract

The mechanism of action of a novel anti-HIV antibiotic, pradimicin A, has been studied using cell-free (MT-4 cells) and cell to cell (MOLT-4 and MOLT-4/HIVHTLV-3B cells) HIV infection systems. The data indicate that (1) preincubation of the cells with HIV at 0 degrees for 1 hr, followed by the addition of pradimicin A and further incubation at 37 degrees, resulted in a complete inhibition of infection while preincubation at 37 degrees did not. Similar data were obtained with the coculture between MOLT-4 and MOLT-4/HIV cells. (2) Virus treated with pradimicin A followed by washing did not show any inhibition on subsequent HIV binding to cells. (3) The inhibitory effect of pradimicin A on HIV infection was prevented by mannan but not by other sugars tested. Mannan, however, did not interfere with the anti-HIV activity of other known inhibitors. (4) Use of EGTA suggested that pradimicin A required Ca ions to exert its anti-HIV activity. These data imply that pradimicin A inhibits an early step in HIV infection, probably through its binding to mannose residues of HIV glycoprotein.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2345961     DOI: 10.1016/0042-6822(90)90016-k

Source DB:  PubMed          Journal:  Virology        ISSN: 0042-6822            Impact factor:   3.616


  12 in total

Review 1.  Antiviral therapy for human immunodeficiency virus infections.

Authors:  E De Clercq
Journal:  Clin Microbiol Rev       Date:  1995-04       Impact factor: 26.132

2.  Pradimicin A, a carbohydrate-binding nonpeptidic lead compound for treatment of infections with viruses with highly glycosylated envelopes, such as human immunodeficiency virus.

Authors:  Jan Balzarini; Kristel Van Laethem; Dirk Daelemans; Sigrid Hatse; Antonella Bugatti; Marco Rusnati; Yasuhiro Igarashi; Toshikazu Oki; Dominique Schols
Journal:  J Virol       Date:  2006-10-18       Impact factor: 5.103

3.  Effects of succinylated concanavalin A on infectivity and syncytial formation of human immunodeficiency virus.

Authors:  T Matsui; S Kobayashi; O Yoshida; S Ishii; Y Abe; N Yamamoto
Journal:  Med Microbiol Immunol       Date:  1990       Impact factor: 3.402

4.  Assays to detect and characterize human immunodeficiency virus type 1 (HIV-1) receptor antagonists, compounds that inhibit binding of the HIV-1 surface glycoprotein, gp120, to the CD4 receptor on human T lymphocytes.

Authors:  J Clancy; A Tait-Kamradt; J Petitpas; M Manousos; P R McGuirk; T Subashi; P Watts; L Wondrack
Journal:  Antimicrob Agents Chemother       Date:  1994-09       Impact factor: 5.191

5.  Pradimicin S, a highly soluble nonpeptidic small-size carbohydrate-binding antibiotic, is an anti-HIV drug lead for both microbicidal and systemic use.

Authors:  Jan Balzarini; Katrien O François; Kristel Van Laethem; Bart Hoorelbeke; Marleen Renders; Joeri Auwerx; Sandra Liekens; Toshikazu Oki; Yasuhiro Igarashi; Dominique Schols
Journal:  Antimicrob Agents Chemother       Date:  2010-01-04       Impact factor: 5.191

6.  The phthalocyanine prototype derivative Alcian Blue is the first synthetic agent with selective anti-human immunodeficiency virus activity due to its gp120 glycan-binding potential.

Authors:  Katrien O François; Christophe Pannecouque; Joeri Auwerx; Virginia Lozano; Maria-Jésus Pérez-Pérez; Dominique Schols; Jan Balzarini
Journal:  Antimicrob Agents Chemother       Date:  2009-08-31       Impact factor: 5.191

7.  Carbohydrate-Binding Non-Peptidic Pradimicins for the Treatment of Acute Sleeping Sickness in Murine Models.

Authors:  Víctor M Castillo-Acosta; Luis M Ruiz-Pérez; Juan Etxebarria; Niels C Reichardt; Miguel Navarro; Yasuhiro Igarashi; Sandra Liekens; Jan Balzarini; Dolores González-Pacanowska
Journal:  PLoS Pathog       Date:  2016-09-23       Impact factor: 6.823

Review 8.  Targeting the glycans of glycoproteins: a novel paradigm for antiviral therapy.

Authors:  Jan Balzarini
Journal:  Nat Rev Microbiol       Date:  2007-08       Impact factor: 60.633

9.  Antiviral activity of carbohydrate-binding agents against Nidovirales in cell culture.

Authors:  F J U M van der Meer; C A M de Haan; N M P Schuurman; B J Haijema; W J Peumans; E J M Van Damme; P L Delputte; J Balzarini; H F Egberink
Journal:  Antiviral Res       Date:  2007-05-21       Impact factor: 5.970

Review 10.  Molecular architecture and therapeutic potential of lectin mimics.

Authors:  Yu Nakagawa; Ito Yukishige
Journal:  Adv Carbohydr Chem Biochem       Date:  2012       Impact factor: 12.200

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.